Post Profile






Another shady business relationship has Wall Street worried about Valeant

Wall Street is beginning to raise questions about a mysterious business distributing drugs for Valeant Pharmaceuticals. Does that sound familiar? Analyst David Maris over at Wells Fargo says the drugmaker has been loath to answer questions about Direct Success, a Florida based company that distributes Valeant's number two product, depression treatment Wellbutrin XL. In fact, when asked about it in September, CEO Joe Papa said he didn't know what it was.
read more

share
See more about: Wall Street

Related Posts


REPORT: Valeant is under criminal investigation

Business & Finance : Business Insider: Money Game

Valeant Pharmaceuticals, the troubled Canadian drugmaker, is under criminal investigation, according to The Wall Street Journal. Federal investigators are considering bringing charges of defrauding investors with its relationship to...

Legal tangle in California may shed light on specialty pharmacies

Business & Finance : Business Insider: Money Game

By David Ingram NEW YORK (Reuters) - As Valeant Pharmaceuticals prepares to defend its drug sales practices to Wall Street on Monday, new details are emerging about the tangled relationships - and litigation - among Valeant’s specia...

It hasn't been this bad for Valeant in months (VRX)

Business & Finance : Business Insider: Clusterstock

Valeant Pharmaceuticals is taking a beating. The shares are down 14% on Monday, at levels they hadn't hit since November. Wall Street is still talking about a 40-page report Wells Fargo analyst David Maris put out about the company ...

Wall Street is passing around this brutal Valeant report and it's dragging the stock down

Business & Finance : Business Insider: Clusterstock

A report from Wells Fargo analyst David Maris circulating around Wall Street dragged Valeant's stock down 7% Friday. Basically Wells is arguing that Valeant's old, successful business model is finished, and the new one it's trying t...

Wall Street dropped a bomb on Valeant right before its Senate hearing

Business & Finance : Business Insider: Clusterstock

Timing is everything. On Wednesday morning Wells Fargo analyst David Maris published a report pointing out that Valeant Pharmaceuticals has raised prices on 16 of its products so far this year. On Wednesday afternoon, Valeant Pharma...

Comments


Copyright © 2016 Regator, LLC